Quantcast
Last updated on April 19, 2014 at 5:20 EDT

Latest Orphan drugs Stories

2011-12-12 15:34:18

Lymphoma and myeloma are both malignant diseases that arise from lymphocytes, a subset of blood cells, and commonly involve lymph nodes and the bone marrow. Although considerable progress has been made in the treatment of these diseases, they remain a significant challenge for patients and their hematologists. New research introducing unique treatment approaches and targets for lymphoma and myeloma will be presented today at the 53rd Annual Meeting of the American Society of Hematology....

2011-12-12 07:00:00

QUÓ°BEC CITY, Dec. 12, 2011 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today reported encouraging preclinical data for its oral anticancer Akt inhibitor, perifosine, in Hodgkin Lymphoma. In vitro data from Hodgkin lymphoma (HL) cell lines showed that perifosine combined with sorafenib induced increased apoptosis, while in vivo data for the same combination treatment for HL significantly increased survival in mice. Data...

2011-12-11 10:00:00

SAN DIEGO, Dec. 11, 2011 /PRNewswire/ -- Lymphoma and myeloma are both malignant diseases that arise from lymphocytes, a subset of blood cells, and commonly involve lymph nodes and the bone marrow. Although considerable progress has been made in the treatment of these diseases, they remain a significant challenge for patients and their hematologists. New research introducing unique treatment approaches and targets for lymphoma and myeloma will be presented today at the 53rd Annual...

2011-12-02 00:22:00

EAST HANOVER, N.J., Dec. 2, 2011 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") will showcase more than one hundred and sixty presentations on data from its robust oncology portfolio at two key medical congresses this month, demonstrating significant advances for patients with cancers and hematological diseases. The CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), held from December 6-10, will feature data presentations from...

2011-11-18 09:40:00

Drug not shown to be safe and effective in breast cancer patients SILVER SPRING, Md., Nov. 18, 2011 /PRNewswire-USNewswire/ --FDA Commissioner Margaret A. Hamburg, M.D., said today she is revoking the agency's approval of the breast cancer indication for Avastin (bevacizumab) after concluding that the drug has not been shown to be safe and effective for that use. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) Avastin will still remain on the market as an approved treatment...

2011-10-26 01:30:00

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced results from a Bayer HealthCare Pharmaceuticals Phase 3 trial evaluating the investigational compound regorafenib (BAY 73-4506) for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard therapies. The trial met its primary endpoint of statistically significant improvement in overall survival. This is the...

2011-10-03 07:00:00

NEW YORK, LONDON and HAMILTON, Bermuda, Oct. 3, 2011 /PRNewswire/ -- Celtic Pharmaceutical Holdings L.P. ("Celtic Pharma") is pleased to announce the completion of enrollment into a maximum dose tolerance study of investigational product Xerecept® (corticorelin acetate) in pediatric patients who were dependent on chronic Decadron (dexamethasone) dosing due to peritumoral brain edema associated with cerebral tumors. In the open label study, 100% of the subjects showed...

2011-09-25 06:03:00

EAST HANOVER, N.J., Sept. 25, 2011 /PRNewswire/ -- Novartis announced new data today from the pivotal Phase III IMPRES clinical trial showing that the investigational therapy QTI571 (imatinib) significantly improved exercise capacity in patients with pulmonary arterial hypertension (PAH) after 24 weeks compared with placebo(1). Evidence indicates that QTI571 targets an underlying cause of PAH by counteracting uncontrolled growth of arterial smooth muscle cells(2). The IMPRES study met...

2011-09-21 16:45:00

Dr Lise Aagaard has been appointed Editor-in-Chief of the new open access journal Orphan Drugs: Research and Reviews, published by Dove Medical Press Auckland, New Zealand (PRWEB) September 21, 2011 Dove Medical Press has announced the appointment of Dr Lise Aagaard as the Editor-in-Chief of the new journal Orphan Drugs: Research and Reviews. This international, peer-reviewed, open access journal will publish original research, reports, reviews and commentaries on all areas of the design...

2011-07-18 15:44:58

Studies Provide Insight to the Oncology Community on New Treatments, Methods to Predict Best Outcomes, and Patient Quality of Life Issues Researchers from the John Theurer Cancer Center at Hackensack University Medical Center presented results from 14 cancer-related studies during the recently concluded American Society of Clinical Oncology (ASCO) Annual Meeting, which took place June 3 "“ 7, 2011 in Chicago. The studies examined new cancer treatments, ways to predict the best treatment...